Boehringer Ingelheim is advancing the development of BI 1291583, a novel cathepsin C inhibitor, for the treatment of non-cystic fibrosis bronchiectasis (NCFB). Following the positive outcomes of the Phase II AIRLEAF trial, which demonstrated a reduction in exacerbation risk among adults with NCFB, the company is preparing to launch the Phase III AIRTIVITY trial in 2025 to further evaluate the efficacy and safety of BI 1291583. This upcoming study aims to enroll approximately 1,680 participants worldwide and will assess the impact of the medication on the frequency of pulmonary exacerbations over a treatment period of up to 18 months.